1. Алексеев В.А. Применение мелоксикама в лечении люмбоишиалгического синдрома. Рус. мед. журн. 2003; 11, 7 (179): 34–41.
2. Насонов Е.Л. Противовоспалительная терапия ревматических болезней. М.: М-Сити, 1996.
3. Никифоров А.С., Коновалов А.Н., Гусев Е.И. Клиническая неврология. В 3 т. М.: Медицина, 2002.
4. Bosch H, Sigmund R, Hettich M. Efficacy and tolerability of intramuscular and oral meloxicam in patients with acute lumbago: a comparison with intramuscular and oral piroxicam. Curr Med Res Opin 1997; 14: 29–38.
5. Caldwell B, Aldington S, Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006; 99: 132–40.
6. Cannon C, Curtis S, FitzGerald G et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 18, 368 (9549): 1771–81.
7. Carrabba M, Paresce E, Angelini M et al. A comparison of the local tolerability, safety and efficacy of meloxicam and piroxicam suppositories in patients with osteoarthritis: a single-blind, randomized, multicentre study. Curr Med Res Opin 1995; 13 (6): 343–55.
8. Celik G, Erkekol F, Bavbek S et al. Long-term use and tolerability of cyclooxygenase-2 inhibitors in patients with analgesic intolerance. Ann Allergy Asthma Immunol 2005; 95 (1): 33–7.
9. Chou R, Kareem A, Snow V et al. For the Clinical Efficacy Assessment Subcommittee of the American College of Physicians and the American College of Physicians/American Pain Society Low Back Pain Guidelines Panel. Diagnosis and Treatment of Low Back Pain: A Joint Clinical Practice Guideline from the American College of Physicians and the American Pain Society. Ann Intern Med 2007; 147: 478–91.
10. Colberg K, Hettich M, Sigmund R, Degner F. The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. Curr Med Res Opin 1996; 13 (7): 363–77.
11. de Grauw J, van de Lest C, Brama P et al. In vivo effects of meloxicam on inflammatory mediators, MMP activity and cartilage biomarkers in equine joints with acute synovitis. Equine Vet J 2009; 41 (7): 693–9.
12. Deyo R, Rainville J, Kent D. What can the history and physical examination tell us about low back pain? JAMA 1992; 268: 760–5.
13. Domingo M, Marchuet M, Culla M, Joanpere R. Meloxicam tolerance in hypersensitivity to nonsteroidal anti-inflammatory drugs. J Investig Allergol Clin Immunol 2006; 16 (6): 364–6.
14. Dreiser R, Le Parc J, Ve´licitat P, Lleu P. Oral meloxicam is effective in acute sciatica: two randomised, double-blind trials versus placebo or diclofenac. Inflamm Res 2001; 50 (Suppl. 1): S17–23.
15. Goei The H, Lund B, Distel M, Bluhmki E. A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 1997; 5 (4): 283–8.
16. Hagen K, Jamtvedt G, Hilde G, Winnem M. Bed rest bad for back pain, ineffective for sciatica. The updated Cochrane Review of bed rest for low back pain and sciatica. Spine 2005; 30: 542–46.
17. Harreby M, Nygaard B, Jessen T et al. Risk factors for low back pain in a cohort of 1389 Danish school childre: an epidemiologic study. Eur Spine J 1999; 8 (6): 444–50.
18. Inotai A, Hanko B, Me´sza´ros A. Trends in the non-steroidal anti-inflammatory drug market in six Central-Eastern European countries based on retail information. Pharmacoepidemiol Drug Saf 2010; 19 (2): 183–90.
19. Jarvik J, Deyo R. Diagnostic evaluation of low back pain with emphasis on imaging. Ann Intern Med 2002; 137: 586–97.
20. Koleck M, Mazaux J, Rascle N et al. Psycho-social factors and coping strategies as predictors of chronic evolution and quality of life in patients with low back pain: A prospective study. Eur J Pain 2006; 10: 1–11.
21. Kumar G, Hota D, Nahar Saikia U. Evaluation of analgesic efficacy, gastrotoxicity and nephrotoxicity of fixed-dose combinations of nonselective, preferential and selective cyclooxgenase inhibitors with paracetamol in rats. Exp Toxicol Pathol 2009 Sep 30.
22. Lai K, Chu K, Hui W et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005; 118: 1271–8.
23. Low Back pain initiavite, WHO, 1999; p. 4.
24. Luo X, Pietrobon R, Sun S et al. Estimates and patterns of direct health care expenditures among individuals with back pain in the United States. Spine 2004; 29: 79–86.
25. Morovic´-Vergles J. Meloxicam – the balance of efficacy and safety. Reumatizm 2008; 55 (2): 85–6.
26. Pountos I, Giannoudis P, Jones E et al. NSAIDS inhibit in vitro MSC chondrogenesis but not osteogenesis. J Cell Mol Med 2010 Jan 11. [Epub ahead of print].
27. Royal College of General Practitioners. Clinical Guidelines for the Management of Acute Low Back Pain. London, Royal College of General Practitioners, 1996 and 1999.
28. Ruperto N, Nikishina I, Pachanov E. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. et al. Arthrit Rheum 2005; 52 (2): 563–72.
29. Sanderson R, Beata C, Flipo R et al. Systematic review of the management of canine osteoarthritis. Vet Rec 2009; 164 (14): 418–24.
30. Senna G, Bilo´ M, Antonicelli L et al. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. Eur Ann Allergy Clin Immunol 2004; 36 (6): 215–8.
31. Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 2007; 370 (9605): 2138–51.
32. UK BEAM Trial Team. United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: effectiveness of physical treatments for back pain in primary care. BMJ 2004; 329: 1377–81.
33. Valat J, Accardo S, Reginster J et al. A comparison of the efficacy and tolerability of meloxicam and diclofenac in the treatment of patients with osteoarthritis of the lumbar spine. Inflamm Res 2001; 50 (Suppl. 1): S30–4.
34. Van Ryn J, Kink-Eiband M, Kuritsch I et al. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol 2004; 44 (7): 777–84.
35. van Tulder MW, Touray T, Furlan A et al. Muscle Relaxants for Nonspecific Low Back Pain: A Systematic Review Within the Framework of the Cochrane Collaboration. Spine 2003; 28 (17): 1978–92.
36. van Tulder M. Low back pain (chronic). Clin Evid 2004; 12: 1657–82.
37. van Tulder M, Becker A, Bekkering T et al. European guidelines for the management of acute nonspecific low back pain in primary care. Eur Spine J 2006; 15 (Suppl. 2): S169–91.
38. Waddell G. The Back Pain Revolution ed. by G.Waddell. 2nd ed. Elsevier Edinburgh. 2004; p. 221–39.
39. Watkins P, Kaplowitz N, Slattery J et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006; 296: 87–93.
40. Wojtulewski J, Schattenkirchner M, Barcel_ P et al. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7,5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br J Rheumatol 1996; 35 (Suppl. 1): 22–28.
41. Wooten J, Blikslager A, Marks S et al. Effect of nonsteroidal anti-inflammatory drugs with varied cyclooxygenase-2 selectivity on cyclooxygenase protein and prostanoid concentrations in pyloric and duodenal mucosa of dogs. Am J Vet Res 2009; 70 (10): 1243–9.